Press Releases

Biothera Pharmaceuticals Presents New Cancer Immunotherapy Research at the 2016 American Association for Cancer Research (AACR) Annual Meeting

EAGAN, MN — April 18, 2016 — Biothera Pharmaceuticals, Inc. today announced research providing new insights into the ability of the Company’s Phase 2 cancer immunotherapy to coordinate innate and adaptive immune responses and enhance the effectiveness of combination therapies. The findings were presented today at the AACR annual meeting, which is taking place in New Orleans, LA, April 16-20, 2016. The company is presenting...

Read More


Biothera Pharmaceuticals to Present at Third Annual Jefferies Immuno-Oncology Summit

EAGAN, MN — April 4, 2016 — Biothera Pharmaceuticals, Inc. today announced that Barry Labinger, Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit on Friday, April 8, 2016 at 1:15p.m. Eastern Time in Boston, Mass. Mr. Labinger will provide an overview of Biothera and its clinical development plans in oncology. About Biothera Pharmaceuticals, Inc.Biothera Pharmaceuticals is a privately held biotechnology company...

Read More


Biothera Announces Presentations at Upcoming American Association for Cancer Research (AACR) Annual Meeting

EAGAN, MN — March 16, 2016 — Biothera Pharmaceuticals Inc. announced today that it will present five scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 16-20 in New Orleans. Three of the posters were selected for the high profile, late-breaking research sessions—sessions devoted to the newest, most exciting research of the year. Details of the presentations are as follows: Poster Presentations:...

Read More


Biothera Pharmaceuticals to Present its Phase 2 Cancer Immunotherapy Data at International Molecular Medicine Tri-Conference

EAGAN, MN — March 10, 2016 — Biothera Pharmaceuticals Inc. today will present data on its Phase 2 cancer immunotherapy Imprime PGG, the Company’s first-in-class, systemically administered beta glucan PAMP (Pathogen Associated Molecular Patterning molecule) at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference 2016, taking place at the Moscone Convention Center, San Francisco. Jeremy Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera...

Read More


Biothera Announces Publication of Imprime PGG Positive Safety Findings and Pharmacokinetic Data from Two Phase 1 Studies

Results published in Investigational New Drugs: The Journal of New Anticancer Agents Imprime PGG (Beta 1,3/1,6 glucan) also has established proof of concept as an immuno-oncology therapy in subsequent single arm and randomized Phase 2 studies With significant milestones anticipated throughout 2016, Biothera is advancing Imprime PGG towards registration trials by 2018 EAGAN, MN — February 25, 2016 — Biothera Pharmaceuticals Inc. today announced the peer-reviewed...

Read More


Biothera Pharmaceuticals Inc. to Present at the 18th Annual BIO CEO & Investor Conference

EAGAN, MN — February 2, 2016 — Biothera Pharmaceuticals Inc. announced today that Barry Labinger, Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 10:00a.m. Eastern Time in New York, NY. Mr. Labinger will provide an overview of Biothera and business update. Biothera Pharmaceuticals Inc. was selected as the winner of the “Most Buzzworthy...

Read More


Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck’s Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer

EAGAN, MN — December 10, 2015 — Biothera Pharmaceutical Inc., today announced plans for a Phase 1b/2 clinical study in non-small lung cancer (NSCLC) patients to evaluate the ability of Biothera’s Imprime PGG to enhance responses to pembrolizumab (Keytruda®), the anti-PD-1 antibody from Merck (NYSE:MRK), known as MSD outside the United States and Canada. Merck will provide funding and clinical supplies of pembrolizumab for the...

Read More


Biothera Pharmaceutical Inc. Appoints Barry Labinger as Chief Executive Officer

EAGAN, MN — December 9, 2015 — Biothera Pharmaceutical Inc. announced today the appointment of Barry Labinger as Chief Executive Officer, effective December 14. Biothera Pharmaceutical is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers. Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome...

Read More


Biothera’s Imprime PGG and Monoclonal Antibody Therapy Alleviates Immune Suppression in Tumor Microenvironment and Increases Cancer Cell Killing

Company to Present New Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting NATIONAL HARBOR, MD — November 6, 2015 — New research provides additional scientific evidence that Biothera’s mid clinical stage cancer immunotherapy Imprime PGG acts as an immune ignition switch that enables the body to recognize and kill tumor cells. The company will present the data today at the Society for Immunotherapy...

Read More


Biothera’s Imprime PGG and Anti-Angiogenic Antibodies Work in Concert to Re-orient the Immune Microenvironment to Support Cancer Killing, Study Finds

BOSTON, November 6, 2015 — New preclinical research demonstrating the combination of Biothera’s Imprime PGG and anti-angiogenic antibodies re-orients the immune microenvironment to suppress tumor growth will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Imprime PGG is an immune potentiator that represents the next step in immune oncology. This mid clinical stage cancer immunotherapeutic is a first-in-class, well-tolerated,...

Read More



Page 2 of 612345...Last »